Device Trial Radar · NCT07608549
FLASH Pilot Phase 1 Safety Study
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 31, 2029
Primary completion
Dec 31, 2030
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Lesley A. JarvisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dartmouth College
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this research trial is to study the safety of electron FLASH treatment for cutaneous lymphoma lesions. In addition, investigators will confirm the accuracy of dose and dose rate delivery of electron FLASH therapy using on-patient dosimetry measurements. Researchers will also determine the response rates of cutaneous lymphomas treated with a low radiation dose in a single fraction using electron UHDR treatments, followed by an assessment of radiation related skin toxicity.
Conditions
- Cutaneous Lymphoma
Interventions
IntraOp Mobetron UHDRDevice
The Mobetron UDHR System provides electrons for precision radiotherapy of lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The FLASH enabled Mobetron System is intended to deliver electron FLASH radiotherapy to participants with cutaneous lymphoma lesions located in extremities.
LinacRadiation
Conventional radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences and grades of all grade-3-or-higher skin toxicities (according to CTCAE version 6.0) that are attributed to the electron FLASH treatment procedure [FLASH treatment safety and toxicity profile].Time frame: 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.